New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio


SOUTH SAN FRANCISCO, Calif.–()–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Genentech neuroscience portfolio across six therapeutic areas, including Evrysdi™ (risdiplam) for spinal muscular atrophy (SMA), Ocrevus® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton’s tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III…



Click here to view the original article.

S&P/ASX 200 
7,065.60  2.10  0.03%  
ALL ORDINARIES 
7,328.00  2.20  0.03%  
Dow Jones Industrial Average 
34,200.67  164.67  0.48%  
S&P 500 
4,185.47  15.05  0.36%  
NASDAQ Composite 
14,052.34  13.54  0.10%  
NYSE COMPOSITE (DJ) 
16,186.30  69.50  0.43%  
FTSE 100 
7,036.79  17.26  0.25%  
DAX PERFORMANCE-INDEX 
15,464.78  5.03  0.03%  
Nikkei 225 
29,685.37  2.00  0.01%  
HANG SENG INDEX 
29,106.15  136.44  0.47%